Lenalidomide in Combination With Dexamethasone in Newly Diagnosed Multiple Myeloma - The ASCO Post
Tailored lenalidomide regimen benefits older patients with multiple myeloma
POMALYST® (pomalidomide) Treatment Option
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial - The Lancet Oncology
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Cancers | Free Full-Text | How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma
VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma | 2 Minute Medicine
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma | 2 Minute Medicine
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
REVLIMID® (lenalidomide) - Official Patient Website
Lenalidomide concentration profiles over time and after dexamethasone... | Download Scientific Diagram
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America | NEJM
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
547-Lenalidomide and dexamethasone oral | eviQ
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Ixazomib, lenalidomide, and dexamethasone as first-line therapy: Tourmaline-MM2 trial update
